Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Fossils unearthed in Morocco are first from little-understood period of human evolution - 2‘This year nearly broke me as a scientist’ – US researchers reflect on how 2025’s science cuts have changed their lives
- 3It's been 20 years since MTV's golden couple split. These producers saw it all unravel.
- 4The Electric Toyota Hilux Is Finally here, But It's Not Cheap
- 5Ski Resorts Universally: A Colder time of year Wonderland Guide
- Ukraine to get up to 100 French-made Rafale fighter jets
- Discovering a true sense of harmony: Contemplation and Care Practices
- The Eastern Bongo, Kenya’s Rare Forest Antelope on the Brink
- From Modesty to Administration: Self-improvement in Interactive abilities
- Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- Defense Minister Katz moves to extend IDF service to 36 months
- Step by step instructions to Choose the Right Auto Crash Legal counselor for Your Case
- Israel and Lebanon's Hezbollah continue to trade attacks
